FCGR2A and COVID-19: Therefore, the specificity of the newly developed SARS-CoV-2 IgG FcγR ELISAs was challenged with an extensive panel of 790 pre-COVID-19 negative-control samples originating from Europe (n = 139), South America (n = 40), Asia (n = 20), and Africa (n = 591).